Image Source: Zacks Investment Research Ionis has collaborations with leading drugmakers/biotech companies, such as ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Ionis Pharmaceuticals ... and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

CARLSBAD, Calif., April 16, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m. Eastern Time ...

CARLSBAD, Calif., April 03, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks ...

Ionis Pharmaceuticals IONS signed a license agreement ... AstraZeneca, Novartis and GSK are its partners for Wainua, pelacarsen and bepirovirsen, respectively. The FDA approved Wainua in December ...

Data from the Novartis and GSK-partnered drug studies are expected in 2025 and 2026, respectively. Ionis currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks ...